Hikma launches generic Vascepa
Icosapent ethyl capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Hikma has launched icosapent ethyl capsules in a 0.5 gm dose, the generic of Amarin’s Vascepa.
The product is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Hikma’s generic product is not approved for any other indication of Vascepa.
[Read more: Hikma to launch 4 generics in Canada]
Icosapent ethyl capsules, 0.5 gm had a market value of approximately $22 million for the 12 months ending January 2023, according to IQVIA.
[Read more: Hikma to acquire Custopharm]